A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
